Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades

Fangming Song, Chengming Wei, Lin Zhou, An Qin, Mingli Yang, Jennifer Tickner, Yuanjiao Huang, Jinmin Zhao, Jiake Xu

Research output: Contribution to journalArticle

11 Citations (Scopus)
80 Downloads (Pure)

Abstract

Bone destruction or osteolysis marked by excessive osteoclastic bone resorption is a very common medical condition. Identification of agents that can effectively suppress excessive osteoclast formation and function is crucial for prevention and treatment of osteolytic conditions such as periprosthetic joint infection and periprosthetic loosening. Luteoloside, a flavonoid, is a natural bioactive compound with anti-inflammation and anti-tumor properties. However, the effect of Luteoloside on inflammation-induced osteolysis is unknown. Here, we found that Luteoloside exhibited a strong inhibitory effect on lipopolysaccharide (LPS)-induced osteolysis in vivo. In addition, Luteoloside suppressed RANKL-induced osteoclast differentiation and abrogated bone resorption in a dose-dependent manner. Further, we found that the anti-osteoclastic and anti-resorptive actions of Luteoloside are mediated via blocking NFATc1 activity and the attenuation of RANKL-mediated Ca2+ signaling as well as NF-κB and MAPK pathways. Taken together, this study shows that Luteoloside may be a potential therapeutic agent for osteolytic bone diseases associated with abnormal osteoclast formation and function in inflammatory conditions.

Original languageEnglish
Pages (from-to)1723-1735
Number of pages13
JournalJournal of Cellular Physiology
Volume233
Issue number2
DOIs
Publication statusPublished - 1 Feb 2018

Fingerprint

Osteolysis
Osteogenesis
Lipopolysaccharides
Bone
Osteoclasts
Bone Resorption
Inflammation
Bone Diseases
Flavonoids
luteolin-7-glucoside
Tumors
Joints
Bone and Bones
Infection
Neoplasms

Cite this

Song, Fangming ; Wei, Chengming ; Zhou, Lin ; Qin, An ; Yang, Mingli ; Tickner, Jennifer ; Huang, Yuanjiao ; Zhao, Jinmin ; Xu, Jiake. / Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades. In: Journal of Cellular Physiology. 2018 ; Vol. 233, No. 2. pp. 1723-1735.
@article{2ae9907f80c744869b1ef372fef51761,
title = "Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades",
abstract = "Bone destruction or osteolysis marked by excessive osteoclastic bone resorption is a very common medical condition. Identification of agents that can effectively suppress excessive osteoclast formation and function is crucial for prevention and treatment of osteolytic conditions such as periprosthetic joint infection and periprosthetic loosening. Luteoloside, a flavonoid, is a natural bioactive compound with anti-inflammation and anti-tumor properties. However, the effect of Luteoloside on inflammation-induced osteolysis is unknown. Here, we found that Luteoloside exhibited a strong inhibitory effect on lipopolysaccharide (LPS)-induced osteolysis in vivo. In addition, Luteoloside suppressed RANKL-induced osteoclast differentiation and abrogated bone resorption in a dose-dependent manner. Further, we found that the anti-osteoclastic and anti-resorptive actions of Luteoloside are mediated via blocking NFATc1 activity and the attenuation of RANKL-mediated Ca2+ signaling as well as NF-κB and MAPK pathways. Taken together, this study shows that Luteoloside may be a potential therapeutic agent for osteolytic bone diseases associated with abnormal osteoclast formation and function in inflammatory conditions.",
keywords = "luteoloside, osteoclast, osteolysis, RANKL",
author = "Fangming Song and Chengming Wei and Lin Zhou and An Qin and Mingli Yang and Jennifer Tickner and Yuanjiao Huang and Jinmin Zhao and Jiake Xu",
year = "2018",
month = "2",
day = "1",
doi = "10.1002/jcp.26084",
language = "English",
volume = "233",
pages = "1723--1735",
journal = "Journal Cellular Physiology",
issn = "0021-9541",
publisher = "John Wiley & Sons",
number = "2",

}

Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades. / Song, Fangming; Wei, Chengming; Zhou, Lin; Qin, An; Yang, Mingli; Tickner, Jennifer; Huang, Yuanjiao; Zhao, Jinmin; Xu, Jiake.

In: Journal of Cellular Physiology, Vol. 233, No. 2, 01.02.2018, p. 1723-1735.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades

AU - Song, Fangming

AU - Wei, Chengming

AU - Zhou, Lin

AU - Qin, An

AU - Yang, Mingli

AU - Tickner, Jennifer

AU - Huang, Yuanjiao

AU - Zhao, Jinmin

AU - Xu, Jiake

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Bone destruction or osteolysis marked by excessive osteoclastic bone resorption is a very common medical condition. Identification of agents that can effectively suppress excessive osteoclast formation and function is crucial for prevention and treatment of osteolytic conditions such as periprosthetic joint infection and periprosthetic loosening. Luteoloside, a flavonoid, is a natural bioactive compound with anti-inflammation and anti-tumor properties. However, the effect of Luteoloside on inflammation-induced osteolysis is unknown. Here, we found that Luteoloside exhibited a strong inhibitory effect on lipopolysaccharide (LPS)-induced osteolysis in vivo. In addition, Luteoloside suppressed RANKL-induced osteoclast differentiation and abrogated bone resorption in a dose-dependent manner. Further, we found that the anti-osteoclastic and anti-resorptive actions of Luteoloside are mediated via blocking NFATc1 activity and the attenuation of RANKL-mediated Ca2+ signaling as well as NF-κB and MAPK pathways. Taken together, this study shows that Luteoloside may be a potential therapeutic agent for osteolytic bone diseases associated with abnormal osteoclast formation and function in inflammatory conditions.

AB - Bone destruction or osteolysis marked by excessive osteoclastic bone resorption is a very common medical condition. Identification of agents that can effectively suppress excessive osteoclast formation and function is crucial for prevention and treatment of osteolytic conditions such as periprosthetic joint infection and periprosthetic loosening. Luteoloside, a flavonoid, is a natural bioactive compound with anti-inflammation and anti-tumor properties. However, the effect of Luteoloside on inflammation-induced osteolysis is unknown. Here, we found that Luteoloside exhibited a strong inhibitory effect on lipopolysaccharide (LPS)-induced osteolysis in vivo. In addition, Luteoloside suppressed RANKL-induced osteoclast differentiation and abrogated bone resorption in a dose-dependent manner. Further, we found that the anti-osteoclastic and anti-resorptive actions of Luteoloside are mediated via blocking NFATc1 activity and the attenuation of RANKL-mediated Ca2+ signaling as well as NF-κB and MAPK pathways. Taken together, this study shows that Luteoloside may be a potential therapeutic agent for osteolytic bone diseases associated with abnormal osteoclast formation and function in inflammatory conditions.

KW - luteoloside

KW - osteoclast

KW - osteolysis

KW - RANKL

UR - http://www.scopus.com/inward/record.url?scp=85032971547&partnerID=8YFLogxK

U2 - 10.1002/jcp.26084

DO - 10.1002/jcp.26084

M3 - Article

VL - 233

SP - 1723

EP - 1735

JO - Journal Cellular Physiology

JF - Journal Cellular Physiology

SN - 0021-9541

IS - 2

ER -